News

AndexXa is currently under EMA review for reversal of Factor Xa inhibition in patients experiencing a life-threatening or uncontrolled bleed and for patients requiring urgent or emergency surgery.

In April of this year, the companies announced an upfront payment from Gilead of $400m for the acquisition of Nimbus Apollo, and another potential $800m in development-related payments;

The new offering, IBM Watson for Patient Safety, will run on the Watson Health Cloud. The collaboration will combine Watson's cognitive computing ability with Celgene's deep history and experience

According to the people familiar with the matter, Japan’s Takeda Pharmaceutical is expected to acquire Salix gastroenterology business unit for around $10bn. In April 2015, Valeant acquired Salix

Toprol-XL is an extended-release tablet that belongs to a family of high blood pressure medications dubbed beta-blockers. It is indicated for control of hypertension, angina, and heart failure.

The regulator issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for sarilumab, an investigational interleukin-6 receptor (IL-6R) antibody for the treatment of adult patients

Soft Tissue Sarcoma (STS) affects approximately 2.8 in 10,000 people in the EU and a recent statistic estimated 5-year survival rate of 58 % for patients suffering from

PharmaMar submitted the above mentioned application for the antitumor drug of marine origin, Aplidin, in combination with dexamethasone given the positive results obtained from the ADMYRE study. Plitidepsin

Study 311 is a global multicenter, single-arm Phase III clinical study of perampanel in approximately 160 patients (ages 4 to less than 12 years) with inadequately controlled partial-onset